Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Turcot syndrome 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hodgkin Disease 2Glioblastoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Biliary Tract Neoplasms 2Advanced Endometrial Cancer 2Tongue Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous NSCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1

Interventions

pembrolizumab 1lenvatinib 1Paclitaxel 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Non-squamous Non-small-cell Lung Cancer × pembrolizumab × Clear all
NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Peking University First Hospital

Phase 2 Not yet recruiting
28 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡